Valerie Vouret-Craviari
Overview
Explore the profile of Valerie Vouret-Craviari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
3917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bedeschi M, Agrawal A, Adinolfi E, Tesei A, Vouret-Craviari V
Purinergic Signal
. 2025 Mar;
PMID: 40072681
Over the past few years, transcriptomics has emerged as a pillar for modern scientific research, enabling the comprehensive profiling of gene expression. The availability of large-scale public datasets, such as...
2.
Belaid A, Romeo B, Rignol G, Benzaquen J, Audoin T, Vouret-Craviari V, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409962
The past several years have provided a more profound understanding of the role of microbial species in the lung. The respiratory tract is a delicate ecosystem of bacteria, fungi, parasites,...
3.
Janho Dit Hreich S, Humbert O, Pace-Loscos T, Schiappa R, Juhel T, Ilie M, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927931
Methods: This ancillary study includes 195 patients with metastatic non-small-cell lung cancer (NSCLC) treated with ICI in monotherapy, either pembrolizumab or nivolumab. Plasmatic levels of IL-18-related compounds, comprising the inhibitor...
4.
Janho Dit Hreich S, Juhel T, Leroy S, Ghinet A, Brau F, Hofman V, et al.
Elife
. 2024 Feb;
12.
PMID: 38300690
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease associated with progressive and irreversible deterioration of respiratory functions that lacks curative therapies. Despite IPF being associated with a dysregulated...
5.
Abad C, Demeules M, Guillou C, Gonde H, Zoubairi R, Tan Y, et al.
J Nanobiotechnology
. 2024 Jan;
22(1):27.
PMID: 38212782
Background: The pro-inflammatory ATP-gated P2X7 receptor is widely expressed by immune and non-immune cells. Nanobodies targeting P2X7, with potentiating or antagonistic effects, have been developed. Adeno-associated virus (AAV)-mediated gene transfer...
6.
Janho Dit Hreich S, Hofman P, Vouret-Craviari V
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298187
Cancer is the leading cause of death worldwide despite the variety of treatments that are currently used. This is due to an innate or acquired resistance to therapy that encourages...
7.
Janho Dit Hreich S, Juhel T, Hofman P, Vouret-Craviari V
Biol Proced Online
. 2023 Jan;
25(1):1.
PMID: 36600200
Background: P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties...
8.
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454832
Lung cancer is the most common cancer worldwide. Despite recent therapeutic advances, including targeted therapies and immune checkpoint inhibitors, the disease progresses in almost all advanced lung cancers and in...
9.
Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V
Purinergic Signal
. 2021 Aug;
17(4):619-631.
PMID: 34347213
Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care...
10.
Douguet L, Janho Dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, et al.
Nat Commun
. 2021 Jan;
12(1):653.
PMID: 33510147
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive...